PMS-SALBUTAMOL ORAL LIQUID SOLUTION

Kraj: Kanada

Język: angielski

Źródło: Health Canada

Kup teraz

Składnik aktywny:

SALBUTAMOL (SALBUTAMOL SULFATE)

Dostępny od:

PHARMASCIENCE INC

Kod ATC:

R03CC02

INN (International Nazwa):

SALBUTAMOL

Dawkowanie:

0.4MG

Forma farmaceutyczna:

SOLUTION

Skład:

SALBUTAMOL (SALBUTAMOL SULFATE) 0.4MG

Droga podania:

ORAL

Sztuk w opakowaniu:

250 ML

Typ recepty:

Prescription

Dziedzina terapeutyczna:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

Podsumowanie produktu:

Active ingredient group (AIG) number: 0108887004; AHFS:

Status autoryzacji:

APPROVED

Data autoryzacji:

2003-05-28

Charakterystyka produktu

                                PRODUCT MONOGRAPH
PR
PMS-SALBUTAMOL ORAL LIQUID
_Salbutamol Sulphate Solution _
_0.4 mg Salbutamol/mL _
Bronchodilator
(beta
2
-adrenergic agonist)
PHARMASCIENCE INC.
Date of Revision:
6111 Royalmount Ave, Suite 100
February 5, 2015
Montréal, Québec
H4P 2T4
www.pharmascience.com
Control no. : 179272
_pms-SALBUTAMOL ORAL LIQUID Product Monograph _
_Page 2 of 21_
PRODUCT MONOGRAPH
PR
PMS-SALBUTAMOL ORAL LIQUID
Salbutamol Sulphate Solution
CLINICAL PHARMACOLOGY
Salbutamol produces bronchodilation through stimulation of beta
2
-adrenergic receptors in
bronchial smooth muscle, thereby causing relaxation of bronchial
muscle fibres. This action is
manifested by an improvement in pulmonary function as demonstrated by
spirometric
measurements.
A measurable decrease in airway resistance is typically observed 30
minutes after an oral dose of
salbutamol sulphate. The maximum improvement in pulmonary function
usually occurs after 2 to
3 hours, and significant bronchodilator activity has been observed to
persist for 6 hours or
longer.
INDICATIONS AND CLINICAL USE
Prevention or relief of bronchospasm due to bronchial asthma, chronic
bronchitis and other
chronic bronchopulmonary disorders in which bronchospasm is a
complicating factor.
CONTRAINDICATIONS

Patients who are hypersensitive to salbutamol sulphate or any of the
ingredients of
pms-SALBUTAMOL ORAL LIQUID. For a complete listing of ingredients, see
PHARMACEUTICAL INFORMATION, COMPOSITION.

Patients with tachyarrhythmias.

Children 2 years of age and younger.

As a tocolytic in patients at risk of premature labour or threatened
abortion.
_pms-SALBUTAMOL ORAL LIQUID Product Monograph _
_Page 3 of 21_
WARNINGS
USE OF ANTI-INFLAMMATORY AGENTS: In accordance with the present
practice for
asthma treatment, concomitant anti-inflammatory therapy should be part
of the regimen if
salbutamol needs to be used on a regular daily basis (see DOSAGE AND
ADMINISTRATION).
It is essential that the physician instruct the patient in the need
for further evaluation if the
patien
                                
                                Przeczytaj cały dokument
                                
                            

Wyszukaj powiadomienia związane z tym produktem